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Abstract 
Acute myocardial infarction (MI) remains a leading cause of morbidity and mortality 
worldwide. Accompanying MI is myocardial ischemia/reperfusion (MI/R) injury, which 
results in cardiac contractile dysfunction and additional myocardial cell death. MIIR 
injury is initiated in pati by mitochondrial-derived reactive oxygen species due to 
mitochondrial membrane potential collapse and uncoupling of the electron transport 
chain, which may be due to mitochondrial fission in MIIR. Mitochondrial fission is in 
turn associated with shotiening/fragmentation of mitochondria, decreased ATP 
production, and is thought to promote cardiac contractile dysfunction and post-reperfused 
cardiomyocyte loss, leading to increased infarct size. Therefore, inhibiting mitochondrial 
fission may be an effective new strategy to salvage injured cardiomyocytes during MI/R. 
Dynamin related protein 1 (Drp1) is a cytosolic GTPase that promotes mitochondrial 
fission via interaction with various outer mitochondrial membrane proteins. Mdivi-1 
(MW= 353.22 g/mol), a mitochondrial fission inhibitor that acts by selectively inhibiting 
Drp1 GTPase activity, was used to test this strategy. Isolated perfused rat heatis subjected 
to 30 min ischemia and 90 min reperfusion exhibited significantly higher infarct size 46% 
± 3% (n=9) compared to sham heatis (minimal infarct size), which did not undergo 1/R. 
Administration ofMdivi-1 (25 J.!M) for 5 min following ischemia significantly reduced 
infarct size to 24% ± 2% (n=7), as compared to control 1/R heatis (p< 0.01). Moreover, 
control 1/R hearts showed significantly compromised peak rates of rise in the first 
derivative ofleft ventricular developed pressure ( +dP/dtmax) of 656.98 ± 90.02 mmHg/s 
and left ventricular developed pressure (LVDP) of 35.36 ± 5.06 mmHg compared to 
IV 
sham hearts (+dP/dtmax of 1998.69 ± 195.87 mmHg/s and LVDP of76.69 ± 9.12 mmHg) 
at the end ofthe experimental protocol (both p<0.01). By contrast, Mdivi-1 treatment 
significantly improved +dP/dtmax to 1101.83 ± 132.24 mmHg/s, LVDP to 49.85 ± 2.69 
mmHg, compared to untreated control 1/R hearts at the end of reperfusion (both p<0.05). 
These results suggest that inhibition of mitochondrial fission may be an effective strategy 
to mitigate heali injury in MI patients. 
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Introduction 
Summary 
Coronary heart disease (CHD) provoking myocardial infarction (MI) is the 
leading cause of death and disability worldwide (Hausenloy and Y ellon, 2013). Current 
treatments for MI include primary percutaneous coronary intervention (PPCI), 
thrombolytic therapy, aspirin, nitrates, beta-adrenergic and calcium channel blockers, and 
angiotensin conve1ting enzyme inhibitors (Mayo Clinic Staff, March 06, 2014). However, 
a large pmtion of cardiomyocyte death seen in MI patients is caused by myocardial 
ischemialreperfusion (MI/R) injuries, a problem not resolved in any of these 
contemporary treatments. For this reason, innovative strategies to protect the heart are 
necessary to improve clinical outcomes in patients who have suffered MI. 
MIIR injury is a pathological condition involving the generation of reactive 
oxygen species (ROS) leading to cardiomyocyte death following a decrease in blood 
flow, a condition called ischemia, and the restoration of oxygen rich blood, an event 
called reperfusion. Similar diseases such as diabetes, atherosclerosis, and obesity serve as 
high risk factors for CHD. Prolonged myocardial ischemia leads to cardiac tissue 
damage, myocardial infarction, and abnmmal heart rhythms (Mayo Clinic Staff, March 
06, 2014). Timely reperfusion to the heart is currently the most effective therapeutic 
intervention to reduce acute MIIR injury and potentially save a patient's life. Reperfusion 
is most commonly achieved clinically via PPCI, otherwise known as angioplasty 
(Hausenloy and Yell on, 2013 ). Threading a catheter through the inguinal femoral or 
radial mtery and the related blood vessels until the blockage site in the specific coronary 
artery is found is how cardiologists perfmm PPCI. A balloon is then inflated to widen 
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the narrowed or obstructed mteries, thus allowing blood to again flow through the artery 
to perfuse the myocytes in the ischemic area to reduce the infarct size (Cohen, 2014). 
However, it is valuable to understand that although reperfusion is effective in limiting 
final infarct size, the act of reperfusion will also contribute to infarct size (Figure 1 ). In 
other words, aside from bringing oxygenated blood to the ischemic tissue, the initial 
subsequent effects ofreperfusion paradoxically augment injury, rather than alleviate the 
unfavorable environment. Therefore, prevention ofreperfusion injury can further 
attenuate infarct size. Many mechanisms are involved in reperfusion injury. Recently, 
mitochondrial fission, or shortening/fragmentation of mitochondria, has been shown to be 
associated with MI/R and is thought to promote cardiac contractile dysfunction and post-
reperfused cardiomyocyte loss, leading to increased infarct size (Disatnik et al., 2013; 
Sharp et al., 2014). 
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Figure 1. Illustration of the individual contributions of acute MI injury and myocardial 
reperfusion injury to final MI size in MI patients up to 24 hours following PPCI. 
(Hausenloy and Yellon 2013). 
Overview of Ischemia 
The mechanism of ischemia involves an oxygen-depleted period, which halts 
oxidative phosphorylation along the mitochondrial membrane, leading to mitochondrial 
membrane depolarization, ATP depletion, and inhibition of myocardial contractile 
function (Figure 2). Additionally, cellular metabolism switches to anaerobic glycolysis 
due to oxygen depletion during ischemia, resulting in the accumulation of lactic acid, 
which lowers intracellular pH to less than 7.0. At this pH level, a protein pore on the 
mitochondrial inner membrane called the mitochondrial petmeability transition pore 
(MPTP) is assembled, but remains closed. The further accumulation of protons due to 
lactate accumulation activates the sodium-hydrogen (Na+-H+) ion exchanger in order to 
mitigate the unwanted hydrogen ions by extruding them for sodium ion entry. At the 
same time, A TP depletion slows the sodium-potassium (N a+-K+) pump, which relies on 
ATP for its function, further increasing the intracellular Na+ overload (Hausenloy and 
Yellon, 2013). The responding mechanism to increased intracellular Na+ is the two-
sodium-calcium (2Na+-Ca2+) ion exchanger. This exchanger is driven by concentration 
gradients on either side of the cellular membrane and thus leads to excessive Ca2+ influx. 
A rise in mitochondrial Ca2+ may also occur under such conditions, but is only modest, 
since the mitochondria are largely de-energized in the absence of oxygen (Allen et al., 
1993; Griffiths and Halestrap, 1995; Miyata et al., 1992). Without oxygen's role as the 
final electron acceptor in oxidative phosphorylation, ATP generation wanes. Without 
ATP, the myosin head is unable to reset itself for myofibril contracture. Therefore, 
myofibril contracture is inhibited during this period. The acidic conditions developed 
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during ischemia due to lactic acid generation, prevent the opening of the MPTP and 
further lead to cardiomyocyte contracture inhibition. 
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Figure 2. Mechanism oflschemia in cardiomyocytes. (Adapted from Hausenloy and 
Yellon 2013). 
Overview of Reperfusion 
Reperfusion on the other hand is the intervention used to return freshly 
oxygenated blood to the ischemic tissue, but consequently reactivates the electron 
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transpmi chain in the mitochondria, generating ROS (Figure 3). It does this by catalyzing 
the one-electron reduction of molecular oxygen (02), forming superoxide anion (02•- ). 
Superoxide is convetied to hydrogen peroxide (H20 2) through the action of superoxide 
dismutases (SODs) both within the mitochondria and in the cytosol (Hamanaka and 
Chandel, 2010). 
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Figure 3. Complexes 1 and 3 in the electron transport chain are responsible in releasing 
0 2- during I/R (Adapted from Szeto and Schiller, 2011). 
ROS also mediate MI/R injury by inducing the opening of the MPTP, act as neutrophil 
chemoattractants, and mediate dysfunction of the sarcoplasmic reticulum. This leads to 
increased intracellular Ca2+ from the sarcoplasmic reticulum, cell membrane damage due 
to lipid peroxidation, enzyme denaturation, and direct oxidative damage to DNA 
(Hausenloy and Yellon, 2013). Washout oflactic acid upon reperfusion and reactivation 
of the Na+-H+ ion exchanger to extrude excess hydrogen ions restores the pH to normal 
levels. Excess Ca2+ is driven into the mitochondria upon the restoration of the 
mitochondrial membrane potential, which can also induce MPTP opening. In response to 
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the release ofROS, cytokines, and activated complement, neutrophils (i.e. 3-4 hours post-
reperfusion) accumulate in the infarcted myocardial tissue (Tsao et al., 1990). The 
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mitochondria, though dysfunctional, are now able to produce ATP again because 0 2 is 
available. ATP availability in combination with increased Ca2+ emergence from the 
sarcoplasmic reticulum results in myofibril hypercontracture (Hausenloy and Yell on, 
2013). Hypercontracture occurs due to this excess Ca2+ binding to troponin in the 
cardiomyocytes causing confmmational changes in troponin that allow more tropomyosin 
to move away from the myosin-binding sites on actin. Thus, more cross-bridges are 
fmmed between actin and myosin, triggering extra contraction. This high intracellular 
Ca2+ and myofibril hypercontracture is responsible for diastolic dysfunction (increase in 
diastolic pressure). Diastolic dysfunction is detrimental because the elevated pressure 
prevents adequate relaxation of the ventricles to refill with blood to pump to the rest of 
the body. Moreover, the myocardial tissue cannot receive the crucial blood supply that it 
requires because it is during diastole that the coronary blood flow is perfused to these 
cardiomyocytes. 
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Figure 4. Mechanism of reperfusion in cardiomyocytes. (Adapted from Hausenloy and 
Yellon 2013). 
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MI/R injury involves a series of events in which oxidative stress is crucial to 
initiating these events. Unfmiunately, administration of antioxidants has not been 
effective in clinical trials. Therefore, targeting ROS sources may lead to a novel 
treatment strategy. It is essential to cultivate understanding of the mechanisms in which 
MIIR injury occurs and develop innovative methods to attenuate MI/R injury. Doing so 
will help to preserve post-reperfused cardiac function, limit infarct size, reduce mortality, 
and improve the quality of life for MI patients. Cunently, mitochondrial derived ROS 
may be an impmiant source of oxidative stress during MI/R (Kloner et al., 2012; Sharp et 
al., 2014). 
Mitochondrial Significance 
Mitochondria, which are extremely plentiful in cardiomyocytes (i.e. up to 40%) 
due to the high demand for ATP, are central to both cellular metabolism and apoptosis. 
ROS produced by the mitochondria during stress can be hmmful to their own lipids, 
proteins, and DNA and lead to mitochondrial dysfunction (Hamanaka and Chandel, 
2010). However, low levels ofROS can be beneficial to the cardiovascular system. These 
low levels of ROS play a role in vascular smooth muscle cell proliferation and 
differentiation, along with angiogenesis. Increased ROS lead to loss of mitochondrial 
membrane potential, which signals mitochondrial fission and mitophagy (Kim et al., 
2007; Lemasters et al., 1998; Scherz-Shouval and Elazar, 2011). Therefore, identifying 
the inhibitory mechanisms of mitochondrial fission is essential in understanding 
cardiomyocyte viability during MI/R. 
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Mitochondrial Dynamics 
Mitochondria are highly dynamic organelles that frequently change their shape in 
response to a cell's metabolic demands or pathological conditions. Various 
mitochondrial-shaping proteins control mitochondrial fission and fusion events. Among 
them are human fission protein 1 (Fis 1 ), mitochondrial fission factor (Mft), and 
mitochondrial elongation factor 1 (MIEF1). These three integral proteins reside on the 
outer mitochondrial membrane and serve as receptors. Mitochondrial fission occurs when 
there is increased fragmentation (i.e. shortening), whereas mitochondrial fusion (i.e. 
elongation) occurs due to increased tethering between two adjacent mitochondria (Zhao 
et al., 2013). These mitochondrial dynamics are regulated via a GTPase called dynamin 
related protein 1 (Drp 1 ), which resides in the cytosol. During an ischemic event such 
MI/R, a calcium-activated phosphatase, calcineurin, becomes activated. This calcineurin 
enzyme will dephosphorylate Drp 1 at a specific serine site called S63 7. Upon 
dephosphorylation, Drp 1 will translocate to one of the three outer mitochondrial 
membrane protein receptors: Fis1, Mff, or MIEFl. When Drp1 interacts with Fis1 or 
Mff, fission is promoted. 
Conversely, when Drp1 interacts with MIEF1, Drp1-driven mitochondrial fission 
is inhibited; fusion is promoted. This may also be in patt due to MIEF 1 
oligodimerization between two adjacent mitochondria. Another possible interaction 
occurs between Fis 1 complexing with MIEF1. Fis 1 will block the inhibitory action 
nmmally exhibited by MIEF1, thus preventing Drp1 from binding to MIEFl. Thereby, 
this interaction will relieve the inhibitory effect on Drp1 (Zhao et al., 2013). 
In addition to MIEFI, mitochondrial fusion is coordinated by three other 
mitochondrial membrane proteins, which include Mitofusin 1 (Mfnl) and Mitofusion 2 
(Mfn2) acting on the outer mitochondrial membrane, and optic atrophy 1 (OPAl), acting 
on the inner membrane (Zhao et al., 2013). Both Mfnl and Mfn2 are attached on the 
outer mitochondrial membrane by two transmembrane pmiions and can form homo- and 
heterodimers through interactions that serve to tether the outer membranes between 
adjacent mitochondria together (Chen et al., 2003; Koshiba et al., 2004). OPAl is 
similarly able to tether opposing inner membranes together, leading to mitochondrial 
inner membrane fusion via GTP hydrolysis (Koshiba et al., 2004). As stated earlier, 
MIEFI also contributes to mitochondrial fusion, independent ofMfnl, Mfn2 and OPAl. 
Mitochondrial fusion allows mitochondria to maintain membrane potential by fusing 
depolarized mitochondria to intact ones, while fission allows the segregation of 
umecoverable mitochondria so they can be eliminated by mitophagy, which is a 
specialized fmm of autophagy (Ikeda et al., 20 15) (Figures 5 and 6). 
Mfn112 
OPA1 
MIEF1 _. 
Fusion 
Figure 5. Proteins involved in mitochondrial fusion. (Adapted from Zhao et. al. 2013). 
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Figure 6. Illustration summarizing mitochondrial fission and fusion events. (Adapted 
from Dorn et al. 2014) (Dorn and Kitsis, 2015). 
Recent studies suggest mitochondrial dynamics may patticipate in MI/R injury 
(Disatnik et al., 2013; Ong et al. , 2010; Qi et al., 2013; Sharp et al., 2014). Previous 
studies have shown during MI/R that Drp1 is a regulator of mitochondrial morphology 
and Drp 1 activation primarily binds to Fis 1, and less to Mff and MIEF -1 , leading to 
mitochondrial fission (Disatnik et al., 2013; Sharp et al., 2014). Fmthermore, 
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mitochondrial fission decreased 0 2 consumption, lowered ATP production, and increased 
ROS generation (Disatnik et al., 2013). By contrast, acute inhibition of excessive 
mitochondrial fission using PliO, a peptide that inhibits Drpl and Fisl interaction, 
attenuated mitochondrial dysfunction and decreased infarct in isolated perfused rat heatts. 
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However, this study did not measure post-reperfused cardiac function (Disatnik et al. , 
2013; Qi et al., 2013). Another mitochondrial fission inhibitor, Mdivi-1, that inhibits the 
Drpl GTPase activity, was shown to improve post-reperfused cardiac function in isolated 
perfused rat heatis, suggesting attenuation of mitochondrial fission (Sharp et al., 2014). 
However, this study did not measure infarct size at the end of the experimental procedure. 
Collectively, these two studies have yielded encouraging results, 
suggesting that attenuation of mitochondrial fission may be an important mechanism to 
limit cardiac dysfunction and cell death in MI/R. However, it is clear that additional 
studies need to be performed with Mdivi-1 and PliO to assess infarct size and cardiac 
function in MI/R respectively. 
Regulation of mitochondrial dynamics via a mutually exclusive Interplay of MIEF1 with Drp1 and Fls1 
Key components of the 
mammalian fission machinery 
Orp1 
Mfl 
Fisl I 
MIEF1 r 
Drp1 Calcineurin 
Figure 7. Regulation of mitochondrial dynamics via Drpl. (Adapted from Zhao et al. 
2013). 
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Role of Mitochondria in Apoptosis 
Mitochondria are fundamental organelles in many apoptotic responses. 
Drp 1 translocation leading to mitochondrial fission plays an essential role in mediating 
mitophagy in mouse embryonic fibroblast cells and Bnip3- (a pro-apoptotic BH3-only 
protein) -induced autophagy in adult cardiomyocytes. Overexpression ofDrp1 has also 
been shown to induce mitochondrial fission, increase apoptosis, and decrease 
mitochondrial membrane potential in cardiomyocytes (Ikeda et al., 2015; Ong et al., 
2010). However, whether this translates to an overall increase in myocardial infarct size 
when exposed to global I (30 min)/R (90 min) has yet to be determined. Agitation of the 
outer mitochondrial membrane often leads to the release of apoptotic factors, namely 
cytochrome c. Fis 1 has previously been shown to cause the release of cytochrome c and 
ultimately apoptosis following the fragmentation of the mitochondrial network (James et 
al., 2003). 
Cytochrome c is mostly localized in the mitochondrial intermembrane space 
under nmmal physiological conditions (Neupett, 1997). Stimulation of Fis 1 via 
interaction with Drp 1 may lead to the release of cytochrome c from mitochondria to the 
cytosol where it activates a caspase family of pro teases, triggering apoptosis (Kraemer et 
al., 1998). Normally, cytochrome c binds to cardiolipin, which is an impmtant component 
of the inner mitochondrial membrane, comprising 20% of the total lipid composition. 
Mitochondrial ROS production is stimulated during the early phase of apoptosis, and 
cardiolipin becomes oxidized by the cardiolipin-cytochrome c complex, which has a 
peroxidase function (Orrenius and Zhivotovsky, 2005). The elevation in Ca2+ levels and 
assembly of the MPTP due to MIIR injury precedes cytochrome c release from the 
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mitochondria. Cytochrome c will then interact with the inositol trisphosphate receptor 
(IP3R) on the endoplasmic or sarcoplasmic reticulum (ER or SR respectively) depending 
on location, causing the ER or SR to release Ca2+. The overall increase in Ca2+ elicits 
fmiher cytochrome c release through the MPTP. Cytochrome c also patiicipates as a 
component of the apoptotic protease-activating factor (Apaf-1). This cytochrome c-Apaf-
1 association results in the formation of the apoptosome protein complex, which can 
recruit and activate pro-caspase 9 (Li et al., 1997). Cytochrome c in turn also activates 
caspase 9, which is a cysteine protease that can then go on to activate caspase 3 and 
caspase 7, which are responsible for cellular apoptosis (Boehning et al., 2003) (Figure 9). 
IP3 Receptor 
Cytochrome c 
ER /SR 
Cytosol 
Complex I Complex Ill Complex II Complex IV ATP Synthase 
Figure 8. Cytochrome c apoptotic pathway. (Adapted from Sigma-Aldrich, Cytochrome 
c schematic). 
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Mdivi-1 
The implications of these mitochondrial dynamics were studied using Mdivi-1 
(Sigma-Aldrich Chemicals, StLouis, MO., MW= 353.22 g/mol), a small molecular 
mitochondrial division inhibitor, which functions by selectively inhibiting Drp 1. The 
chemical formula ofthis drug is 3-(2,4-Dichloro-5-methoxyphenyl)-2,3-dihydro-2-
thioxo-4( 1 H)-quinazolinone, 3 -(2,4-Dichloro-5-methoxyphenyl )-2-sulfanyl-4(3 H)-
quinazolinone (Sigma-Aldrich Staff, 2015). Mdivi-1 is a cell-petmeable molecular 
inhibitor, which directly binds to Drp1, inhibiting its GTPase activity and thus its 
function on Fis1, Mff, or MIEF1 (Ong et al., 2010) (Figures 7 and 9). 
Previous studies have shown that treatment of cardiomyocytes with Mdivi-1 every 
24 hours for 1 week prevented mitochondrial fission and inhibited foreshortening of 
mitochondria (Ikeda et al., 2015). Additionally Mdivi-1 has been shown to be 
cardioprotective in ex vivo LangendorffMI/R rat hearts (Sharp et al. , 2014). However, 
this study group did not cany out reperfusion past 20 min, nor did they observe infarct 
size following experiments. In our study, we extended reperfusion time to 90 min 
following 30 min ischemia. Moreover, we evaluated infarct size at the end of our 
experiments. In principle, Mdivi-1 represents a class of therapeutics for stroke, 
myocardial infarction, and neurodegenerative diseases (Sigma-Aldrich Staff, 2015). 
OCH3 O *CI OC;~I 
N SH 
Figure 9. Mdivi-1 molecular structure. (Adapted from Sigma-Aldrich). 
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Hypothesis 
We hypothesize that Mdivi-1, when given during reperfusion in isolated perfused 
rat hemis following thitiy minutes of global ischemia, will provide cardioprotective 
effects. This study will evaluate these cardioprotective effects by measuring cardiac 
function and infarct size of each myocardium throughout the experiments. We will cany 
out reperfusion for a total of ninety minutes post-ischemia. We hypothesize that the use 
ofMdivi-1 will significantly reduce infarct size and preserve post-reperfused cardiac 
function when compared to untreated control I/R hemis. The outcomes of this research 
will benefit heati attack and organ transplantation patients in attenuating IIR-induced 
organ damage. 
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Methods 
Langendorf{ Heart Preparation 
The Institutional Animal Care and Use Committee of the Philadelphia College of 
Osteopathic Medicine approved all animal protocols perfmmed in this study. This study 
utilized Sprague-Dawley rats whose weights ranged from 275-325 g. They were 
anesthetized through a peritoneal injection of pentobarbital sodium (60 mg/kg) and 
heparin (1000 U) to prevent coagulation. Upon opening the peritoneum, 8 mL of blood 
was drawn from the abdominal aorta using a 20-gauge needle fastened to a 1 0 mL 
syringe, containing 1 mL of citrate phosphate buffer. The heatt was isolated from the rat 
and perfused with a modified Krebs ' buffer through the ascending amta. The aorta was 
cannulated to the perfusion needle using surgical suture and lowered into a 160 mL 
water-jacketed reservoir containing 37°C Krebs' buffer to provide the preload for the 
heatt. A constant pressure of 80 rnmHg, aerated with 95% 0 2 and 5% C02, a temperature 
of37°C, and a pH between 7.35- 7.45 was maintained using the Langendorffhemt 
preparation (Blakeman et al., 2012). The Krebs' buffer is composed of the following: 25 
mM NaHC03-, 17 mM dextrose, 5.9 mM KCl, 120 mM NaCl, 0.5 mM EDTA, 2.5 mM 
CaCb, and 1.2 mM MgCb. The blood sample was placed in a centrifuge for 1 0 min at 
10,000 g and 4°C to isolate plasma. A pressure transducer was insetted into the left 
ventricle from the base of the heatt. See Figure 1 0 for the perfused hemt preparation. 
Baseline readings are carried out to 15 min to achieve accuracy as well as to ensure a 
stable cardiac function. Following stable baseline recordings, Krebs' buffer flow was 
blocked to induce ischemia. After 30 min, the flow was resumed along with either 5 mL 
of plasma for the control I/R hemts, or 5 mL of plasma plus 25 f!M ofMdivi-1 (Sigma-
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Aldrich Chemicals, StLouis, MO., MW= 353.22 g/mol) delivered using an infusion 
pump (Harvard Apparatus, Holliston, MA) via a three-way stopcock proximal to the 
hemt. Mdivi-1 is purchased from Sigma-Aldrich in the form of a white powder stored at -
20°C, which is then solubilized with the organosulfur compound dimethyl sulfoxide 
(DMSO) for direct infusion to the Langendorf[ ex vivo heart (final DMSO concentration 
0.1% ). The plasma/buffer, or plasma/buffer with drug was delivered at an infusion rate of 
1 mL/min. An illustrated version of this protocol is diagramed in Figure 11. An infusion 
recording was taken initially at 2 min and a reperfusion recording every 5 min thereafter 
for a 90 min reperfusion period (Blakeman et al. , 2012). LVDP, which is the left 
ventricular end-systolic pressure (L VESP) minus left ventricular end-diastolic pressure 
(LVEDP), and the maximal rate ofLVDP (+dP/dtmax) and minimum rate ofLVDP (-
dP/dtmin) were taken every 5 min during baseline and reperfusion. Coronary flow was 
measured using a flow meter (T106, Transonic Systems, Inc., Ithaca, NY) and a pressure 
transducer was (SPR-524, Millar Instruments, Inc., Houston, TX), inserted through the 
mitral valve and into the left ventricle to record cardiac function data. Data were recorded 
using a Powerlab Station acquisition system (AD Instruments, Grand Junction, CO). After 
90 min ofreperfusion, the hemt was removed from the perfusion needle, frozen at -20°C, 
and cross-sectioned from apex to base into 2 mm pieces. The sections were subjected to 
1% triphenyltetrazolium chloride (TTC) staining for 15 min at 37°C. This helped to 
distinguish viable tissue, which stained red, from dead tissue, which did not stain. The 
infarct size is calculated as a percentage of dead tissue to total tissue weight. 
Figure 10. Langendorffheart preparation . 
.... ~_sa_:_i~-li-ne __ _. . ._I ~-~c_m h-i~_m_i_a ___ __,l~ .... ~-oe_!_i~_rf_u_s_io_n ____ __.l. I ~~~ining 
t Infusion of plasma ± Mdivi-1 
Figure 11. Protocol of isolated perfused rat heart for I/R injury. 
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Treatment Groups 
1) Sham Hearts: Sham or (placebo) hearts were not subjected to ischemia, unlike the 
control I/R hea1ts. This group is used to see whether the isolated heart with Krebs' 
buffer perfusion can maintain cardiac function throughout the experimental 
protocol (i.e. 135 min). After 15 min of initial baseline recordings, Krebs' buffer 
was allowed to continually flow for an additional30 min. The Krebs' buffer is 
then followed by 5 mL infusion of Sprague-Dawley rat plasma for a 90 min 
recording period. The sham hemts will have nearly normal cardiac function 
throughout the experimental period with little to no visible infarcted tissue. This 
group of hearts was used to demonstrate that indeed normal cardiac function 
could be maintained outside the body throughout the experimental period. 
2) MIIR Hemts (untreated, I/R control): Following stable baseline readings, 
ischemia was induced in the hea1ts for 30 min by stopping the flow of Krebs' 
buffer. After 30 min of ischemia, reperfusion was started by restoring the flow of 
Krebs' buffer, which would continue for 90 min with the infusion of 5 mL of 
plasma immediately at the beginning of reperfusion. Control or untreated MI/R 
hemts were used to determine the cardiac dysfunction and infarct size caused by I 
(30 min)/R (90 min) compared to sham hemts and to drug-treated MI/R hemts. 
This was performed to determine if the drug had a true effect on either cardiac 
function or infarct size. Control hearts subjected to I (30 min)/R (90 min) showed 
a compromised cardiac function and a larger infarct size compared to sham hemts. · 
3) MIIR Hearts treated with Mdivi-1: These hemt preparations underwent 30 min of 
ischemia. Reperfusion began by restoring the flow of Krebs' buffer for 90 min 
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with the combined infusion of 5 mL of plasma and 25 ~M ofMdivi-1 during the 
first 5 min ofreperfusion (Sharp et al., 2014). Mdivi-1 treated MI/R hearts were 
used to detetmine the drug's effects on post-reperfused cardiac function and 
infarct size when compared to untreated control MI/R hearts. 
Table 1. MIIR Treatment groups 
Groups Sample size (n) 
Sham 5 
Control I/R 9 
Mdivi-1 (25J-LM) 7 
Isolation of Plasma 
Approximately 8 mL of blood was removed from the rat's abdominal amia. 1 mL 
of citrate phosphate buffer (Sigma Chemical Co., St. Louis MO) was then added before 
the plasma was isolated. The blood was than centrifuged at 10,000 Gat 4°C for 10 min. 
The plasma was decanted (5 mL) and used in all treatment groups. The plasma was 
prepared depending on the treatment group and then infused into the isolated heati via the 
three-way stopcock via a syringe infusion pump (Harvard Apparatus, Holliston, MA) at 1 
mL/min for the first 5 min of reperfusion. 
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TTC Staining and Measurement of Infarct Size 
After 90 min of reperfusion, the hearts were placed in -20°C for 30 min and were 
cross-sectioned from apex to base in 2 mm thick sections. The hearts were stained with 
TTC to detect the infarct size. The 2 mm sections were then placed in a water incubator at 
3 7°C for 15 min. Photographs were taken of each side of each stained section. The viable 
tissue stained red due to the TTC being reduced to 1,3,5-triphenylfmmazan (TPF) in 
response to the dehydrogenase activity (Umemoto, 1985). The dead tissue remained 
unstained due to the loss of the dehydrogenase enzyme from the damaged cell. The 
unstained tissue is excised, weighed, and then recorded using Microsoft Excel software. 
The infarct size is calculated by the weight ratio of unstained tissue to the total weight of 
each 2 mm section. 
Statistical Analysis 
All statistical data in the text and figures are presented as means± S.E.M, and 
analyzed by ANOVA using post hoc analysis with the Student-Newman-Keuls test for 
the cardiac function and infarct size. p<0.05 was considered statistically significant. 
22 
Results 
Cardiac Function 
Multiple parameters of cardiac function were measured and quantified over the 
course of the experiments. Initial data measurements represent the last recording taken 
following a stable baseline ( ~ 15 min) and final measurements represent completion of the 
90 min time point of reperfusion. The cardiac function parameters quantified for each 
experiment include LVDP, +dP/dtmax, LVESP, -dP/dtmitl> LVEDP, heart rate, and 
coronary flow. The experiments conducted include sham, control I/R, or I/R + Mdivi-1 
(25 )lM) treated heatis. 
Left Ventricular Developed Pressure (L VDP) 
Figure 12 diagrams the initial vs. final L VDP values for each experimental group. 
There was no significant difference observed in initial L VDP recordings among all 
groups. Sham heatis maintained a LVDP of76.69 ± 9.12 rnrnHg throughout the whole 
time course of the experiment. By contrast, untreated control I/R hearts show a L VDP of 
35.36 ± 5.06 rnrnHg at 90 min ofreperfusion, which was significantly lower compared to 
sham heatts. Notably, administration ofMdivi-1 (25 )lM) significa,ntly improved LVDP 
to 49.85 ± 2.69 rnrnHg at 90 min ofreperfusion compared to untreated control I/R heatts. 
The control 1/R and Mdivi-1 treated hea1ts resulted in a LVDP of38 ± 6% and 59± 4% 
of initial baseline recordings, respectively, compared to baseline. Figure 13 illustrates the 
time course of L VDP among sham, control I/R, and I/R + Mdivi-1 (25 )lM) treated 
hemts. Untreated control I/R hemts showed significantly lower L VDP throughout the 
whole reperfusion period. Fmthetmore, Mdivi-1 significantly improved L VDP at the 5, 
10, 15, 20, 25, 30, 35, 40, 80, 85 and 90 min points of reperfusion compared to untreated 
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control I/R hemis (p<0.05). The final LVDP for the Mdivi-1 drug treated group was 
significantly increased compared to the untreated control I/R group. These data indicate 
that Mdivi-1 (25 11M) significantly restored post-reperfused cardiac contractile function 
(LVDP) compared to untreated control I/R hemis. Refer to Figures 12 and 13 . 
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Figure 12. Initial vs. final L VDP for sham, control I/R, and I/R + Mdivi-1 hearts. 
(*p<0.05) Mdivi-1 vs. IIR. 
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Figure 13. Time course ofLVDP for Sham, I/R, and IIR + Mdivi-1 hemis. Mdivi-1 (25 
11M) given at reperfusion for the duration of 5 min significantly restored early and late 
post-reperfused cardiac contractile function (LVDP) compared to untreated I/R hemis 
(*p<0.05, * *p<O.O 1 ). 
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Maximal Rate of Rise in Left Ventricular Pressure (+dP/dtmax) 
Figure 14 diagrams the initial vs. final +dP/dtmax values for each experimental 
group. There was no significant difference observed in initial +dP/dtmax recordings among 
all groups. Sham hemis maintained a +dP/dtmax of 1998.69 ± 195.87 mmHg/s throughout 
the whole time course of the experiment. By contrast, untreated control I/R heatis showed 
a +dP/dtmax of 656.98 ± 90.02 mmHg/s at 90 min of reperfusion, which was significantly 
lower, compared to sham hearts. Markedly, administration of Mdivi-1 (25 f.LM) improved 
+dP/dtmax to 1101.83 ± 137.24 mmHg/s at 90 min ofreperfusion compared to untreated 
control I/R hearts. The control I/R and I/R + Mdivi-1 hemis resulted in a +dP/dtmax of28 
± 4%, and 50± 7% respectively, compared to baseline. Figure 15 illustrates the time 
course of +dP/dtmax among sham, control IIR, and I/R + Mdivi-1 (25 f.LM) treated hemis. 
Untreated control I/R hearts showed significantly lower +dp/dtmax values throughout the 
whole reperfusion period. Fmihe1more, Mdivi-1 significantly improved +dp/dtmax at 5, 
10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 75, 80, 85, and 90 min compared to the 
control I/R hearts (p<0.05). The final +dp/dtmax for the Mdivi-1 drug treated group was 
significantly increased compared to the untreated control IIR group. These data indicate 
that Mdivi-1 given at reperfusion for the duration of 5 min significantly restored post-
reperfused cardiac contractile function (+dP/dtmax) compared to untreated control I/R 
hemis. Lastly, sham experiments recovered to near baseline recordings (>90%). See 
Figures 14, 15 and Table 2. 
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Figure 14. Initial vs. final +dP/dtmax for sham, control 1/R, and 1/R + Mdivi-1 (25 j..tM). 
(*p<0.05) Mdivi-1 vs. 1/R. 
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Figure 15. Time course of +dP/dtmax for Sham, 1/R, and 1/R + Mdivi-1 hearts. Mdivi-1 
(25 f!M) given at reperfusion for the duration of 5 min. significantly restored post-
reperfused cardiac contractile function (+dP/dtmax) compared to untreated I/R hearts 
(*p<0.05, **p<0.01). 
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Table 2. Initial vs. Final L VDP and +dP/dtmax comparison 
(*p<0.05) compared to control I/R 
Initial L VDP Final Initial Final 
(mmHg) LVDP +dP/dtmax +dP/dtmax 
(mmHg) (mmHg/s) (mmHg/s) 
Sham 91.91 ± 4.95 76.69 ± 9.12 2280.13 ± 92.13 1998.69 ± 195.87 
(n=S) 
Control I/R 95.35 ± 3.81 35.36 ± 5.06 2382.65 ± 73.38 657.0 ± 90.02 
(n=9) 
I/R + Mdivi-1 85.105 ± 3.3 49.848 ± 2.69 * 2270.27 ± 88.15 1101.83 ± 132.24 * 
(25 J!M) 
(n=7) 
Left Ventricular End Systolic Pressure (L VESP) 
Another measure of cardiac contractility includes the left ventricular end systolic 
pressure (L VESP). Figure 16 diagrams the initial vs. final L VESP values. Sham hemis 
maintained a LVESP of 83.66 ± 10.26 mmHg throughout the whole time course of the 
experiment. Conversely, untreated control I/R hearts demonstrated an increased LVESP 
of90.85 ± 4.98 mmHg at 90 min ofreperfusion, which was not significantly altered, 
compared to sham hemis. Administration of Mdivi-1 (25 )lM) did not affect L VESP at 90 
min of reperfusion (1 01.34 ± 7. 7 mmHg) compared to untreated control 1/R hearts. These 
data indicate there was no significant difference observed in L VESP across each 
experimental group. Refer to Figure16. 
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Figure 16. Initial vs. final L VESP for sham, control I/R, and IIR + Mdivi-1 (25 ~-tM). 
Maximum Rate of Fall in Left Ventricular Pressure (-dP/dtmin) 
Figure 17 diagrams the maximal rate of fall in the first derivative of left 
ventricular pressure -dP/dtmin· This parameter is used to quantify cardiac relaxation, or 
diastolic function. There was no significant difference observed in initial recordings for-
dP/dtmin and LVEDP among all groups. Sham hearts maintained a -dP/dtmin of -1238.56 ± 
152.12 mmHg/s throughout the whole time course of the experiment. Conversely, 
untreated control 1/R hearts show a -dP/dtmin of -624.93 ± 67.76 mmHg/s at 90 min of 
reperfusion, which was significantly lower, compared to sham hearts. Administration of 
Mdivi-1 (25 ~-tM) did not improve -dP/dtmin at 90 min ofreperfusion (-700.491 ± 50.14 
mmHg/s) compared to untreated control I/R hearts. See Figure 17. 
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Sham {n=5) IIR {n=9) 1/R + Mdivi-1 25uM (n= 7) 
Figure 17. Initial vs. fmal -dp/dtmin for sham, control I/R, and I/R + Mdivi-1 (25 )lM). 
Left Ventricular End Diastolic Pressure (LVEDP) 
Another measure of diastolic function, or cardiac relaxation includes the left 
ventricular end diastolic pressure (L VEDP). Figure 18 diagrams the initial vs. final 
L VEDP values. Sham hearts maintained a L VEDP of 6.97 ± 1.49 mmHg throughout the 
whole time course of the experiment. Conversely, untreated control I/R heatis show a 
LVEDP of54.169 ± 5.84 mmHg at 90 min ofreperfusion, which was significantly 
higher, compared to sham hemis. Administration ofMdivi-1 (25 )lM) did not affect 
LVEDP at 90 min ofreperfusion (51.492 ± 7.72 mmHg) compm·ed to untreated control 
I/R hearts. These data indicate there was no significant difference observed in LVEDP for 
drug treated and untreated control I/R hemi groups. Refer to Figure 18. 
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Figure 18. Initial vs. final L VEDP for sham, control 1/R, and 1/R + Mdivi-1 (25 )lM). 
Heart Rate & Coronary Flow Rate 
The integrated cardiac parameters include heati rate, coronary flow rate, and 
infarct size. Figures 19 and 20 diagram the initial vs. final heart rates and coronary flow 
rates for each experimental group, respectively. Sham hemis maintained a hemi rate of 
267.33 ± 11.72 BPM throughout the whole time course of the experiment. Conversely, 
untreated control 1/R hemis show a hemi rate of289.54 ± 33.74 BPM at 90 min of 
reperfusion, which was not significantly different, compared to sham hemis. 
Administration ofMdivi-1 (25 )lM) did not affect heart rate at 90 min ofreperfusion 
(240.298 ± 11.27 BPM) compared to untreated control 1/R hemis. These data indicate 
there was no significant difference observed in hemi rates for all experimental 1/R heart 
groups. Refer to Figure 19. 
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Figure 19. Initial vs. final heati rate for sham, control 1/R, and I/R + Mdivi-1 (25 11M). 
Figure 20 diagrams initial vs. final coronary flow rates. Sham hemis maintained a 
flow rate of 15.29 ± 2.34 mL/min throughout the whole time course of the experiment. 
However, untreated control I/R hemts displayed a flow rate of7.93 ± 0.59 mL/min at 90 
min of reperfusion, which was significantly lower, compared to sham hearts. 
Administration ofMdivi-1 (25 11M) did not increase flow rate at 90 min ofreperfusion 
(7.16 ± 0.57 mL/min) compared to untreated control 1/R hemts. These data indicate there 
was no significant difference observed in coronary flow rates for drug treated and 
untreated control 1/R heart groups. Refer to Figure 20. 
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Figure 20. Initial vs. final coronary flow rate for sham, control I/R, and I/R + Mdivi-1 
(25 ).LM). 
Cardiac Infarct Size 
Following each experiment, TTC staining was used to asce11ain the infarct size 
after 30 min of ischemia (global ischemia; the whole heart is at risk) and 90 min of 
reperfusion. Figure 21 depicts three photographs taken from representative left 
ventriclular cross-sections from each treatment group. The sham heart only showed 
minimal infarct size. However, the untreated control IIR hearts demonstrated larger 
infarct size, mainly located in the mid-myocardial tissue. By contrast, Mdivi-1 treated I/R 
healis showed smaller infarct size, when compared to untreated control I/R healis. Figure 
22 summarizes the weight ratio of infarcted to at risk tissue for sham, control IIR, and I/R 
+ Mdivi-1. Mdivi-1 hemts (25 ).LM) significantly reduced infarct size to 24% ± 2% (n=7) 
compared to untreated control I/R hearts (n=9) that had an infarct size of 46% ± 3% (** 
p<O.Ol). 
Sham 1/R 1/R + Mdivi-1 
Figure 21. Representative left ventricular heart cross sections of sham, 1/R, and IIR + 
Mdivi-1, subjected to TTC staining. Viable tissue stained red, while the infarcted tissue 
remained unstained (white). 
0.7~--------------------------------------~ 
• Sham (n=5) • 1/R (n=9) • 1/R + Mdivi-1 25 uM (n=7) 
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Figure 22. Weight ratios of infarcted/at risk left ventricular tissue in sham, 1/R, and 1/R + 
Mdivi-1 as determined by TTC staining. ** p<0.01 Mdivi-1 vs. IIR. 
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Discussion 
Summary of Major Findings 
The major findings from this study are listed as follows. Control IIR hearts 
displayed compromised cardiac function and increased infarct size following I (30 min)/ 
R (90 min) of reperfusion. Mdivi-1 (25 ~M) treated I (30 min)/ R (90 min) hearts 
significantly improved post-reperfused cardiac function and reduced infarct size 
compared to control I/R hearts. 
Cardiac Dysfunction and Infarct under 1/R 
Under IIR conditions, we observed cardiac contractile dysfunction. Control I/R 
hearts showed compromized contractility such as reduced LVDP, +dP/dtmax, and 
increased L VESP. Normally, oxygen present in the the vasculature provides the 
mitochondrial electron transport chain with the final electron acceptor it requires to 
synthesize ATP. Additionally, Ca2+ stored in the SR becomes available to bind to 
troponin sites on tropomyosin, leading to conformational changes that expose the myosin 
binding sites on the actin filament. This increase in Ca2+ plus ATP availablity provides 
the power necessary for the myocardium to contract. Likewise, the reuptake of Ca2+ into 
the SR allows myofibril relaxation. 
However, during an ischemic event such as in MIIR, oxygen becomes 
unavailable. Decreased 0 2 renders a decrease in A TP, inhibition of myofibril contracture, 
and a change to anerobic respiration. Anerobic respiration increases hydrogen ions, 
which stimulates the Na+-H+ ion exchanger, increasing intracellular Na+. The 2Na+-Ca2+ 
ion exchanger attemps to mitigate Na+ ions by extruding them for Ca2+ ions, which 
ultimately leads to increased intracellular Ca2+ concentrations, even during diastole. This 
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cascade of events aids in assembly of the the MPTP and dismpts the mitchondrial 
innetmembrane potential. Morever, increased Ca2+ activates the Drpl GTPase, which 
augments mitochondrial fission, oxidative stress, and ultimately autophagy (Hausenloy 
and Yellon, 2013; Sharp et al., 2014). These ischemic events account for signifcant drops 
in all cardiac function parameters (LVDP, +dP/dtmax, LVESP, LVEDP, -dP/dtmin, and 
heart rate) during 3 0 min of ischemia in our experiment. 
The restoration of blood during reperfusion, though necessary to salvage what 
undamaged tissue remains, causes additional myocardial cell injury. By washout oflactic 
acid (generated during ischemia), and reintroduction of molecular 02, the mitochondrial 
electron transpmt chain reactivates, generating ROS and disrupting the SR. Ca2+ release 
from the SR in combination with newly available A TP, lead to myofibril hypercontrature 
and opening of the MPTP on the mitochondrial inner membrane. The MPTP further 
uncouples the electron transpmt chain, enhancing ROS generation and releases 
cytochrome c. Furthermore, ROS and cytochrome c contribute to mitochondrial 
autophagy and thus influence MIIR injury (Hausenloy and Yellon, 2013). 
Hypercontracture prevents the myocardium from properly relaxing, and therefore 
influences the increases in both L VESP & L VEDP, and decreases in coronary flow rate, 
as these smTounding myocytes are tightly constricted around the vasculature. Together, 
increased ROS coupled with hypercontracture also clarify the decreased LVDP, 
+dP/dtmax, -dP/dtmiih and increased infarct size when compared to sham hearts. 
Cardioprotective effects of Mdivi-1 
By using Mdivi-1 we targeted the GTPase Drp1, which nmmally leads to 
mitochondrial fission upon MIIR. The calcium overload induced by 1/R, subsequently 
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activates calcineurin, which desphosphylates the S637 site on Drp1, leading to Drp1 
translocation to the mitochondrial outer membrane proteins. After Drp 1 binding to these 
proteins (e.g. Fis1 and Mff) the Drp1 GTPase induces mitochondrial fragmentation (i.e. 
fission). Mdivi-1 however inhibits the Drp1 GTPase, thus attenuating mitochondrial 
fission. Normally, mitochondrial fission is involved with cell cycle progression to 
accommodate energy demands. However, during I/R excessive mitochondrial fission 
leads to decreased A TP and cardiac function and increased oxidative stress, cell death 
and ultimately infarct size. Therefore, attenuating the aforementioned processes will 
ultimately salvage cardiac tissue and function. Maintaining mitochondrial number and 
size provides an additional function whereby mitochondria may act to buffer calcium 
overload (Disatnik et al., 2013; Ong et al., 2010; Qi et al., 2013; Sharp et al., 2014). 
Figure 23 depicts a flow diagram of this process. 
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Figure 23. Overview ofDrpl activation pathway. (Adapted from Sharp et al. 2014). 
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The Effects ofMdivi-1 (2SJ!M) on Cardiac Function and Infarct Size 
For each experiment conducted, the same parameters were consistently measured, 
LVDP, +dp/dtmax, -dp/dtmin, heart rate, coronary flow, LVESP, LVEDP and infarct size. 
The Mdivi-1 treated group showed a significant increase in post-reperfused LVDP and 
+dp/dtmax compared to the untreated control I/R group. Moreover, the notewmthy results 
observed in cardiac function correspond to infarct size in the Mdivi-1 treated group. The 
infarct size recorded in the Mdivi-1 treated group was significantly reduced (24% ± 2%) 
compared to the untreated control I/R group (46% ± 3%). 
In our Langendorf£ ex vivo herut model, we measured left ventricular function 
upon I/R injury because the left ventricle has more cardiomyocyte mass and thus requires 
more blood to perfuse the tissues systemically. Consequently, the L VDP is used to 
measure this damage. L VDP is obtained by subtracting the end diastolic pressure from 
the systolic pressure. The foundation behind using 25 J.!M of Mdivi-1 in our ex vivo 
Langendorf[ model as the optimal concentration, was detetmined from previous studies 
(Sharp et al., 2014). The time course ofMdivi-1 treatment for LVDP is shown above in 
Figure 13. The time course data for LVDP exhibited statistical significance from 
reperfusion 5 min to 40 min and from reperfusion 80 min to 90 min. The loss of 
significant improvement ofLVDP from reperfusion 45 min to 75 min may be due to the 
different recovery pattern between Mdivi-1 treated and control I/R hearts. From Figure 
13, Mdivi-1 quickly improved LVDP from reperfusion 5 min and reached the plateau 
around 40 min, then L VDP started to slightly drop until the end of reperfusion. By 
contrast, L VDP in control IIR heruts showed compromised function at the beginning of 
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reperfusion, then slowly recovered and reached the plateau around 45 min of reperfusion, 
and slightly dropped around 75 min ofreperfusion. In summary, Mdivi-1 treatment 
quickly restored post-reperfused LVDP, which is very critical for maintaining cardiac 
function for MI patients. 
We also observed +dP/dtmax in the left ventricle to measure the peak rates of rise 
in the first derivative. This gives us an idea of how quickly the heart is contracting (i.e. 
mmHg/s) before, during, and after MI/R injury. The time course for +dP/dtmax also 
revealed a statistically significant improvement (p<0.05) throughout the entire 90 min 
experiment, minus the 65 min mark, compared to untreated control I/R hea1is in Figure 
15. 
Additionally, the initial vs. final cardiac function readings were diagramed above 
in the results. Refer to Figures 14-20. The results of the initial versus final graphs of 
LVDP and +dp/dtmax were statistically significant (p<0.05) when given Mdivi-1 (25 J..LM) 
compared to untreated control I/R hemis. This suggests that the Mdivi-1 drug treated 
hemi group considerably improved in these parameters compared to the untreated control 
I/R hemi group. No significant difference was observed between initial vs. final results 
for -dP/dtmilh heart rate, coronary flow rate, LVESP, or LVEDP compared to the 
untreated control IIR hemis. However, it should be noted that the Mdivi-1 treated group 
revealed a trend to increase L VESP and decrease L VEDP compared to the control I/R 
groups. Hence, this indicates the rational for a statistically significant L VDP outcome. 
Infarct size was evaluated at the end of experiments using the TTC staining 
procedure. Infarct size was analyzed based on the weight ratios of five 2 mm slices of 
non-viable (white) to viable (red stained) left-ventricular tissue in the whole hemi. The 
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entire heart is used because the whole heart is at risk during global ischemia. In Figures 
21 and 22, the infarct size is presented visually and graphically, respectively. The Mdivi-
1 treated heart group displayed a significantly reduced infarct size compared to the 
untreated control I/R heart group (p<0.01). These effects may be due to maintenance of 
mitochondrial morphology and function after Mdivi-1 treatment. This suggests that there 
is a beneficial effect in using Mdivi-1 (25 )lM) to limit infarct size caused by MI/R injury. 
In summary, the drug Mdivi-1 (25 )lM) indicated significant recovery in post-reperfused 
cardiac function and reduced infarct size compared to untreated control I/R hearts. 
Comparison to Prior Studies 
Prior studies conducted in our lab have targeted inhibition ofNADPH oxidase and 
mitochondrial derived ROS, but none with regard to mitochondrial division and its 
implication on cardiac function in MIIR injury. Other researchers have observed the 
functions of mitochondrial dynamics, autophagy, and its regulation via Drp1 in murine 
neonatal cardiomyocyte cultures and in myocardial I/R (Ong et al. , 2010; Sharp et al., 
2014). The results from past studies suggest Drp1 is a regulator of mitochondrial 
morphology and Drpl activation leads to severe diastolic dysfunction. Additionally, 
Mdivi-1 (25 )lM) exetis cardio protective effects in an ex vivo Langendorf[ heart model 
with respect to attenuating mitochondrial fission and improving post-reperfused cardiac 
function (Sharp et al., 2014). Since prior ex vivo studies only canied out reperfusion to 20 
min and did not assess infarct size, it was interesting to see if an additional 65 min (for a 
total of 90 min of reperfusion) would elicit cardioprotective effects associated with 
reduced infarct size for the extended reperfusion time in our model compared to Sharp et 
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al. Other ex vivo studies suggest that longer reperfusion time is associated with increased 
infarct size (Disatnik et al., 2013). It is now well recognized that Drp1 is an important 
regulator in mitochondrial dynamics, but its interaction with other mitochondrial 
membrane proteins, such as MIEF1, is not well understood in cardiomyocytes (Ikeda et 
al., 2015; Ong et al., 2010; Sharp et al., 2014). Therefore, exclusive assays to precisely 
evaluate the amount of mitophagy/autophagy and particular interventions to regulate 
mitophagy/autophagy seem critical and will be futiher determined in the setting of I/R. 
Studies conducted with Mdivi-1 in the past used a pre-treatment method as well 
as treatment during reperfusion. Rats in the pre-treatment group were given Mdivi-1 (5 
J.!M) 10 min prior to ischemia. They conducted ischemia for 30 min and reperfusion for 
20 min. The pre-treatment significantly lowered diastolic pressures and increased L VDP 
post-I/R compared to untreated control I/R healis (Sharp et al., 2014). Sharp et al. also 
found similar results when giving Mdivi-1 at reperfusion; in this experimental group, 
they used a 25 J.!M dose. Administering the drug during reperfusion (in the same way we 
administered Mdivi-1) is interesting because the mitochondrial fission cascade is set up 
during ischemia. This suggests Mdivi-1 must diffuse quickly through the cell membrane 
to inhibit the GTPase Drp 1. Since any clinically administered therapy is likely to occur 
post MI, this is an essential investigational point that demonstrates remarkably pragmatic 
applications. 
In another study, Mdivi-1 was studied in vivo (0.24 mg/kg (dose 1) or 1.2 mg/kg 
(dose 2); doses equivalent to ex vivo concentrations of 10 and 50 J.!M, respectively) and 
given as a pre-treatment 15 min prior to myocardial ischemia. This group conducted 
ischemia for 30 min and reperfusion for 120 min. A single intravenous bolus ofMdivi-1 
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at dose I did not indicate a significant difference in mean arterial blood pressure or a 
reduction in infarct size compared to the untreated control I/R hemis. However, a single 
intravenous bolus ofMdivi-1 at dose 2 did significantly reduce myocardial infarct size to 
21 ± 2.2% compared to 48 ± 4.5% in the control IIR hearts where p<0.05 (Ong et al., 
2010) . However, other studies suggest that doses greater than 30 J.!M Mdivi-1 may 
inhibit ether-a-go-go related gene mediated potassium currents, resulting in an increase in 
cardiac action potential duration (So et. al., 2012). Hence, this mechanism would reduce 
cardiac demand and potentially inhibit oxidative stress via this mechanism. Therefore, it 
would be interesting to test a dose of 0.6 mg/kg, a dose equivalent to 25 J.!M ex vivo, to 
see if such a dose elicits cardioprotective effects and would be more consistent with the 
ex vivo findings repmied in this study. The Ong et. al. study suggests that pre-treatment 
with Mdivi-1 may be useful in protecting the heart as a method to limit infarct size in the 
event of MI. 
In a study conducted by Givvimani et al., Mdivi-1 was assessed for its influence 
on apoptosis via tunel assay and activated caspase-3 staining of mouse cardiac sections of 
8 weeks post-amiic banding (to study pressure overload and left ventricular hypertrophy). 
The tunel assay is a common method for detecting DNA fragmentation that results from 
apoptotic signaling cascades. There was a significant increase in apoptosis in the control 
group, whereas treatment with Mdivi-1 attenuated apoptosis, normalizing to that of the 
sham group (Givvimani et al., 2012). These findings suggest that Mdivi-1 has a favorable 
role in counteracting apoptosis. 
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Future Studies 
This study has provided evidence showing the cardioprotective effects that Mdivi-
1 has on cardiac function and infarct size associated with MI/R injury. However, because 
Mdivi-1 is relatively novel, and mitochondrial dynamics are still under investigation in 
the setting of IIR injury, more questions remain to be thoroughly answered. 
Transmission electron microscopy investigation will provide insight into the role 
that Mdivi-1 plays on mitochondrial fission following I (30 min)/ R (90 min), specifically 
showing quantity and the size of individual mitochondria that accompany MIIR injury. 
One could observe morphological changes leading to mitochondrial fragmentation, and 
count the number of these fragmented mitochondria, which would reflect the relative 
amount of fission in untreated control vs. drug-treated hemts. Likewise, the signaling 
pathways related to mitochondrial fission could be evaluated by co-irnrnunoprecipitation. 
This would also provide a clearer picture when and how these mitochondrial changes 
occur. Fmthermore, it helps to understand the mechanism of action of Mdivi-1 treatment 
when given as pre-treatment or at reperfusion. 
Additionally, the impmiance of evaluating mitochondrial function following 
MIIR injury is crucial to understanding the impact ofMdivi-1 treatment. We can use 
oxygraphy and/or ATP bioluminescent assay kits to measure 0 2 consumption, ATP 
concentrations, and electron transpmi chain function following ex vivo MI/R 
experiments. On the other hand, ROS measurements needs to be observed using Mito 
SOX staining to further confirm the protective effects ofMdivi-1 as suggested by another 
study (Sharp et. al., 2014). 
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If Mdivi-1 can be further confirmed to be cardioprotective in other models, it will 
be worth to evaluate its pharmacokinetic properties. It is unknown which administration 
route would be most effective (i.e. IV, IP, or PO). Similarly, we know little about the 
clearance ofMdivi-1 and the role that it plays on healthy (sham) studies. Furthermore, the 
drug's effective shelf life is unknown. When administered in our model during 
reperfusion, the drug is solubilized in DMSO minutes before it is administered. 
Clinically, could Mdivi-1 be pre-mixed, as the case is with many vial- or auto-injector 
based medications, or must it be prepared at the time of administration, as is the case with 
glucagon? 
Also, the TTC staining technique needs to be improved and should reflect more 
uniformity. Future studies should implement a technique that would be enhance infarct 
size detection, such as planimetry software programs to analyze the color differences in 
viable (red stained) vs. infacted tissue (no stain). This would result in a more absolute 
infarct size measurement. Lastly, TTC staining for infarct size evaluation should be 
blinded in order to avoid biased computations. 
Perfmming westem blotting could generate meaningful infmmation regarding the 
density ofDrpl in the cytosol to that on outer mitochondrial membrane proteins after 
sham studies, under control IIR conditions, and during I/R conditions with Mdivi-1. An 
especially important area of investigation would involve a time course that alters the 
length of ischemia (i.e. 30 min or greater) and reperfusion (i.e. greater than 90 min) to 
assess the effects ofMdivi-1 on Drp1 translocation and its consequent effects on 
mitochondrial fission. This would address the question, whether inhibition of the Drp 1 
GTPase would attenuate the binding affinity to outer mitochondrial membrane proteins. 
Another area of interest would be to investigate markers of apoptosis by the 
presence of caspase-3 and its impmiant role in mitochondrial autophagy will provide 
valuable insights into the amounts of myocardial cell death. 
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Lastly, our ex vivo Langendorffhemi preparation cannot be manipulated by 
changing the pressures, which would be analogous to a car engine that is being studied on 
idle. Mdivi-1 should be evaluated in a working heart ex vivo model, which would mimic 
the heart working more or less difficultly based on its needs, as in the case of an actual 
patient. What then happens to the car engine (heart) if you give the car more or less gas 
(increase or decrease the workload on the hemi)? 
Significance of Findings 
This study suggests that Mdivi-1, when reperfused to myocardial tissue in an ex 
vivo Langendorffhemt model subjected to I (30 min)/ R (90 min) will provide 
cardioprotective benefits by improving post-reperfused cardiac function and reducing 
myocardial infarct size as compared to untreated control I/R hemis. Because this drug is 
adminstered during reperfusion, it provides a pragmatic approach for use in the clinical 
setting. Our results suggest that inhibition of mitochondrial fission may be an effective 
strategy to mitigate heali injury in MI patients. Future studies will test other treatment 
regimens with Mdivi-1 in cell culture studies using HL-1 cells and during in vivo MI/R 
studies using a mouse model. 
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